First results of safety profile of nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC) in NIVES study

Cristina Masini, Carmine Pinto, Giorgia Timon et al.|Annals of Oncology|2019

Cited by 0